$0.01
(Market cap
$17 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
6.6
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-18 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-3.2
-
Debt to Equity
0
-
Book Value
$0.2
-
EPS
$-0.8
-
Face value
--
-
Shares outstanding
15,138,782
10 Years Aggregate
CFO
$-77.42 Mln
EBITDA
$-97.36 Mln
Net Profit
$-101.86 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Biocardia Inc (BCDA)
| -5.6 | 46.0 | 31.1 | -39.2 | -54.5 | -51.5 | -41.0 |
|
BSE Sensex*
| -9.0 | -1.1 | 3.0 | -3.5 | 5.8 | 6.3 | 10.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Biocardia Inc (BCDA)
| -42.7 | -77.7 | -68.4 | 7.7 | -43.9 | -6.0 | -65.9 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Biocardia Inc (BCDA)
|
1.2 | 17.4 | 0.0 | -7.3 | -- | -408.3 | -- | 6.6 |
| 84.9 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 247.9 | 16,261.1 | 1,054.4 | 755.9 | 5.7 | -- | 19 | 9.8 | |
| 72.1 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 54.5 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 105.4 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 351.5 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 533.8 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 600.7 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 344.8 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 |
Shareholding Pattern
View DetailsAbout Biocardia Inc (BCDA)
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous... mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It also provides CardiALLO, an allogeneic mesenchymal stem cell therapy which is in phase II for ischemic heart failure; allogeneic cell therapy platform; and PulmALLO, an allogeneic mesenchymal stem cell therapy for acute respiratory distress syndrome. In addition, the company offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; Heart3D for fusion imaging; and morph DNA and avance steerable introducers. It has a license and distribution agreement with Biomet Biologics, LLC. BioCardia, Inc. is based in Sunnyvale, California. Read more
-
CEO, President & Director
Dr. Peter A. Altman Ph.D.
-
CEO, President & Director
Dr. Peter A. Altman Ph.D.
-
Headquarters
Sunnyvale, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Biocardia Inc (BCDA)
What is the current share price of Biocardia Inc (BCDA) Today?
The share price of Biocardia Inc (BCDA) is $1.18 (NASDAQ) as of 28-Aug-2026 16:00 EDT. Biocardia Inc (BCDA) has given a return of -54.5% in the last 3 years.
What is the current PB & PE ratio of Biocardia Inc (BCDA)?
Since, TTM earnings of Biocardia Inc (BCDA) is negative, P/E ratio is not available.
The P/B ratio of Biocardia Inc (BCDA) is 6.59 times as on 28-Aug-2026, a 27 premium to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-1.63 |
15.02 |
2024 |
-0.75 |
7.15 |
2023 |
-0.09 |
-0.62 |
2022 |
-0.21 |
0.52 |
2021 |
-0.17 |
0.21 |
What is the 52 Week High and Low of Biocardia Inc (BCDA)?
The 52-week high and low of Biocardia Inc (BCDA) are Rs 2.27 and Rs 0.75 as of 31-Aug-2026.
What is the market cap of Biocardia Inc (BCDA)?
Biocardia Inc (BCDA) has a market capitalisation of $ 17 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Biocardia Inc (BCDA)?
Before investing in Biocardia Inc (BCDA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.